The Basal Insulin Market is estimated to be valued at US$ 16.3 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Basal insulin is provided as a slow release, continuous dose of insulin which helps regulate blood sugar levels over an extended period of time in patients with Type 1 diabetes or Type 2 diabetes.

Market Overview:

Basal insulin is used for treatment of diabetes and helps maintain blood glucose levels throughout the day. It works similar to naturally occurring insulin produced by the pancreas. The advantages of basal insulin include extended delivery, reduced risk of hypoglycemia compared to bolus insulin, and helps control overall blood sugar levels. The treatment needs continuous monitoring and improvement in technologies for accurate dosage delivery.

Market key trends:

One of the key trends in the Global Basal Insulin Market Size is the rising popularity of basal-bolus insulin therapy. Basal-bolus therapy involves treatment with both a long-acting basal insulin as well as a faster-acting bolus insulin. This approach closely mimics the way a healthy pancreas releases insulin and helps achieve optimal glucose control. Advancements in insulin delivery techniques such as insulin pumps and pens have further accelerated the adoption of basal-bolus therapy.

Porter’s Analysis

Threat of new entrants: There is moderate threat of new entrants in basal insulin market as it requires huge capital investments and regulatory approvals for R&D and production. Bargaining power of buyers: Buyers have moderate bargaining power as presence of several basal insulin brands provides options but patented products have pricing power. Bargaining power of suppliers: Suppliers have low bargaining power as raw material suppliers are many and patents do not restrict material supply. Threat of new substitutes: Substitute threat is low as no drug class directly replaces basal insulin though lifestyle drugs may impact demand growth. Competitive rivalry: Intense rivalry exists among basal insulin brands with many generics and biosimilars emerging.

SWOT Analysis

Strength: Wide portfolio of long-acting basal insulins, established brands, huge R&D budgets and robust pipeline. Weakness: Patent expiry of top brands, pricing pressure, biosimilar competition. Opportunity: Rising diabetic population, increasing healthcare access and spending in emerging nations. Threats: Alternative therapies availability, non-compliance to lifestyle changes, reimbursement challenges.

Key Takeaways

The global basal insulin market is expected to witness high growth, exhibiting CAGR of 9.8% over the forecast period, due to increasing prevalence of diabetes globally. North America dominates the basal insulin market currently due to high awareness and healthcare spending. Asia Pacific is poised to be the fastest growing market due to rising geriatric population, lifestyle changes and improving access to diabetes treatment.

Key players operating in the basal insulin market are Novo Nordisk, Sanofi, Eli Lilly, Biocon, Gan & Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories, Merck, Wockhardt, Julphar Diabetes, Medtronic, Beta Bionics, Zealand Pharma, MannKind, Peptron, Dexcom, Senseonics, Medtrum Technologies, SOOIL Development, Semma Therapeutics. Novo Nordisk leads the market with its global best-selling brands Levemir and Tresiba. Patent expiries of top brands provide opportunities for biosimilars. Collaboration and licensing deals are gaining traction for pipeline assets.

Read More : https://www.dailyprbulletin.com/basal-insulin-market-forecast-outlook-trend-2023-2030/